StreetInsider.com News Articles

Form 4 PTC THERAPEUTICS, INC. For: Oct 14 Filed by: SCHMERTZLER MICHAEL

Fri, 16 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261016/27198724.html

Truist Securities Starts PTC Therapeutics (PTCT) at Hold

Fri, 16 Oct 2026 05:18:57 -0400

Truist Securities analyst Danielle Brill initiates coverage on PTC Therapeutics (NASDAQ: PTCT) with a Hold rating and a price target of $62.00.

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $60.99 yesterday.

PTC Therapeutics (PTCT) PT Raised to $90 at UBS

Thu, 15 Oct 2026 09:17:42 -0400

UBS analyst Joon Lee raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $90.00 (from $80.00) while maintaining a Buy rating.

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

Thu, 15 Oct 2026 08:00:00 -0400

WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m. ET.

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

Thu, 15 Oct 2026 08:00:00 -0400

Form 4 PTC THERAPEUTICS, INC. For: Oct 09 Filed by: Boulding Mark Elliott

Tue, 13 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261013/27181983.html

Form 4 PTC THERAPEUTICS, INC. For: Oct 07 Filed by: SCHMERTZLER MICHAEL

Fri, 09 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261009/27172335.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Fri, 09 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261009/27171701.html

Form 4 PTC THERAPEUTICS, INC. For: Oct 05 Filed by: Boulding Mark Elliott

Wed, 07 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261007/27162016.html

Form 144 PTC THERAPEUTICS, INC. Filed by: SCHMERTZLER MICHAEL

Wed, 07 Oct 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20261007/27161688.html

RBC Capital Reiterates Sector Perform Rating on PTC Therapeutics (PTCT)

Wed, 07 Oct 2026 05:02:24 -0400

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $85.00 price target on PTC Therapeutics (NASDAQ: PTCT).

The analyst comments "With a $2B+ balance sheet and the pipeline beyond Huntington's being mostly early stage, mgmt has consistently expressed an appetite, even beyond their recent Fabry GTx purchase, for bolt-on deals that would bring in assets to increase top line growth while leveraging their global infrastructure. We took the opportunity to identify potential companies/ assets we think could be on PTCT's radar based on therapeutic area and size. Overall, we see several potential avenues PTCT could go which could synergize

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Tue, 06 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261006/27155527.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Mon, 05 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261005/27149055.html

Form 4 PTC THERAPEUTICS, INC. For: Sep 30 Filed by: STEELE GLENN JR MD PHD

Fri, 02 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261002/27143606.html

Form 144 PTC THERAPEUTICS, INC. Filed by: STEELE GLENN JR MD PHD

Wed, 30 Sep 2026 13:27:00 -0400

si-local-file:///var/storage/secattach/20260930/27127851.html

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 25 Sep 2026 16:30:00 -0400

WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2026, the company approved non-statutory stock options to purchase an aggregate of 51,270 shares of its common stock and 37,995 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 37 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 25 Sep 2026 16:30:00 -0400

PTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition

Tue, 22 Sep 2026 07:49:59 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $137.00 (from $130.00) while maintaining a Overweight rating.

The analyst commented, "Today (9/21), PTC announced that the acquisition of ST-920 (AAVbased gene therapy) for Fabry disease from Sangamo (NC) has been completed. The deal was first announced on 8/12. Recall, ST-920 is in late-stage development, with a rolling BLA submission expected to complete in 4Q26, where just the CMC section remains, with a potential launch in 2027E. Adding ST-920 and its associated payments into our model increases our PT to $137 from $130. The submission is

PTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition

Tue, 22 Sep 2026 07:49:59 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $137.00 (from $130.00) while maintaining a Overweight rating.

Form 8-K PTC THERAPEUTICS, INC. For: Sep 21

Mon, 21 Sep 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260921/27085766.html

PTC Therapeutics acquires Fabry disease gene therapy from Sangamo

Mon, 21 Sep 2026 16:30:21 -0400

PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc., according to a company statement.

PTC said it expects to complete a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration for accelerated approval of ST-920 in the fourth quarter of 2026.

ST-920, also known as isaralgagene civaparvovec, is designed to enable long-term production of the alpha-galactosidase A enzyme, which is deficient in patients with Fabry disease. In clinical studies, the therapy was associated with reductions in globotriaosylceramide levels and a reduction in the

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

Mon, 21 Sep 2026 16:30:00 -0400

– Completion of BLA submission expected in Q4 2026 –

WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

Mon, 21 Sep 2026 16:30:00 -0400

– Completion of BLA submission expected in Q4 2026 –

Form 4 PTC THERAPEUTICS, INC. For: Sep 16 Filed by: SCHMERTZLER MICHAEL

Fri, 18 Sep 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260918/27081317.html

Leerink Assumes PTC Therapeutics (PTCT) at Outperform

Mon, 14 Sep 2026 06:12:02 -0400

Leerink assumes coverage on PTC Therapeutics (NASDAQ: PTCT) with a Outperform rating and a price target of $98.00.

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $66.06 yesterday.